This page shows the latest Gossamer Bio news and features for those working in and with pharma, biotech and healthcare.
The failure of Novartis’ drug also damages the overall hypothesis of DP2 targeting drug candidates, and particularly hurts the prospects of would-be competitor Gossamer Bio. ... If it can disprove the naysayers and bring GB001 to market in asthma,
Nevertheless, Renaissance says biotech IPOs “have been getting bigger, and 2019 could see more well-funded biotechs like Gossamer Bio come public if the poor trading of high-profile Moderna does
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...